Your browser doesn't support javascript.
Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain.
Reiners, Nina; Schnurra, Carolin; Trawinski, Henning; Kannenberg, Judith; Hermsdorf, Thomas; Aebischer, Andrea; Schöneberg, Torsten; Reiche, Sven; Jassoy, Christian.
  • Reiners N; Institute for Medical Microbiology and Virology, Leipzig University Hospital and Medical Faculty, University of Leipzig, Johannisallee 30, 04103, Leipzig, Germany.
  • Schnurra C; Institute for Medical Microbiology and Virology, Leipzig University Hospital and Medical Faculty, University of Leipzig, Johannisallee 30, 04103, Leipzig, Germany.
  • Trawinski H; Division of Infectious Diseases and Tropical Medicine, Department of Medicine II, Leipzig University Hospital, Leipzig, Germany.
  • Kannenberg J; Institute for Medical Microbiology and Virology, Leipzig University Hospital and Medical Faculty, University of Leipzig, Johannisallee 30, 04103, Leipzig, Germany.
  • Hermsdorf T; Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, University of Leipzig, 04103, Leipzig, Germany.
  • Aebischer A; Department of Experimental Animal Facilities and Biorisk Management, Friedrich Loeffler Institute, Federal Research Institute for Animal Health, Greifswald, Insel Riems, Germany.
  • Schöneberg T; Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, University of Leipzig, 04103, Leipzig, Germany.
  • Reiche S; Department of Experimental Animal Facilities and Biorisk Management, Friedrich Loeffler Institute, Federal Research Institute for Animal Health, Greifswald, Insel Riems, Germany.
  • Jassoy C; Institute for Medical Microbiology and Virology, Leipzig University Hospital and Medical Faculty, University of Leipzig, Johannisallee 30, 04103, Leipzig, Germany. Christian.jassoy@medizin.uni-leipzig.de.
Eur J Clin Microbiol Infect Dis ; 40(12): 2645-2649, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1258221
ABSTRACT
SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding domain (RBD), or both proteins. The AUROCs were 0.958 (NP), 0.991 (RBD), and 0.992 (NP/RBD). The RBD- and NP/RBD-based ELISAs showed better performance than the NP-based assay. Simultaneous testing for antibodies against NP and RBD increased the number of true and false positives. If maximum diagnostic sensitivity is required, the NP/RBD-based ELISA is preferable. Otherwise, the RBD-based ELISA is sufficient.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay / COVID-19 Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral / Nucleoproteins Type of study: Diagnostic study Limits: Humans Language: English Journal: Eur J Clin Microbiol Infect Dis Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article Affiliation country: S10096-021-04284-5

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay / COVID-19 Testing / SARS-CoV-2 / COVID-19 / Antibodies, Viral / Nucleoproteins Type of study: Diagnostic study Limits: Humans Language: English Journal: Eur J Clin Microbiol Infect Dis Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article Affiliation country: S10096-021-04284-5